From disease basics to insightful analysis of market dynamics, Glioma | Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing critical aspects of the glioma pharmaceutical market based on detailed primary and secondary market research. Content pillars include a summary of disease etiology, pathophysiology, and drug targets; annualized epidemiological projections, including estimates of diagnosis and/or drug treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including launch timing, positioning, and peak sales of key late-phase drugs; a top-line review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast with supporting tables, figures, and methods.
Markets covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: 8 country-specific interviews with thought leaders.
Epidemiology: Diagnosed incident cases of low-grade glioma (WHO grade I-II), high-grade glioma (anaplastic glioma; WHO grade III), glioblastoma (WHO grade IV; primary cases ), and transformed cases of nonglioblastoma astrocytic glioma (WHO grade I-III; secondary cases).
Population segments in market forecast: First-line glioblastoma (newly diagnosed and transformed nonglioblastoma astrocytic glioma cases), second-line glioblastoma (first recurrence), and third-line glioblastoma (second recurrence).
Phase III: 6 drugs; Phase II: 15 drugs; coverage of selected preclinical and Phase I products.